Evidence map›Paper›PMID 40171353›Full record

ArticleCureus2025

Pericardial Oligometastasis From Merkel Cell Carcinoma Treated With Stereotactic Ablative Radiotherapy.

Jose Miguel C Callueng, Islam Mohamed, Dante D'Urbano, Benjamin Mou

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jose Miguel C CalluengDepartment of Radiation Oncology, BC Cancer Kelowna, Kelowna, CAN.
Islam MohamedDepartment of Radiation Oncology, BC Cancer Kelowna, Kelowna, CAN.
Dante D'UrbanoDepartment of Pathology, Kelowna General Hospital, Kelowna, CAN.
Benjamin MouDepartment of Radiation Oncology, BC Cancer Kelowna, Kelowna, CAN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that often has a poor prognosis due to its propensity for distant metastases. A 74-year-old man with a history of MCC of the left forearm, previously treated with surgery and adjuvant radiotherapy, was found to have an asymptomatic pericardial nodule associated with pericardial effusion on routine follow-up imaging. Subsequent biopsy confirmed metastatic MCC. Restaging demonstrated no other sites of metastases. The pericardial metastasis was treated with stereotactic ablative radiotherapy (SABR) to a dose of 40 Gray (Gy) in five daily fractions. A significant decrease in the size of the pericardial nodule was observed 2.3 months post-SABR, and a clinical complete response was achieved 8.9 months post-SABR. Apart from an asymptomatic mildly increased pericardial effusion, no other acute or late adverse effects were observed. At 40.1 months post-SABR, the patient continued to show a durable response to treatment with no evidence of recurrence. To the best of our knowledge, this case of pericardial oligometastases from MCC treated with SABR is the longest reported duration of response.

Indexed as

isolated cardiac metastasismerkel cell carcinomaoligometastasissbrt (stereotactic body radiotherapy)stereotactic ablative radiation

Identifiers

PMID40171353
PMCPMC11959205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.